Escitalopram Oxalate Tablet 20mg (Escitalopram Oxalate)

Adult dosage

The safety of doses exceeding 20mg per day has not been established. This drug is administered once daily in the morning or evening, regardless of meals. 1) Adults (1) Major depressive disorder: The usual dose is 10mg once daily. The dose may be increased to a maximum of 20mg per day according to the patient's response. If the dose is to be increased to 20mg, it should be done at intervals of at least 1 week. In general, 2-4 weeks are required for antidepressant effects to become apparent. Even after symptoms have resolved, drug treatment for at least 6 months is required to ensure a therapeutic effect. (2) Panic disorder with or without agoraphobia: It is recommended to administer an initial dose of 5mg per day for 1 week, then increase it to 10mg per day. The dose may be increased to a maximum of 20mg per day according to the patient's response. Maximum effect occurs after about 3 months. The safety and efficacy of long-term administration of this drug for more than 10 weeks in the treatment of panic disorder have not been systematically studied. The physician should periodically reassess each patient to determine the need for continued treatment. (3) Social anxiety disorder: The usual dose is 10mg once daily. Generally, 2-4 weeks are required for symptoms to improve. Thereafter, the dose may be reduced to 5mg per day or increased to a maximum of 20mg per day according to the patient's response. Social anxiety disorder is a chronic condition, and continued treatment for 12 weeks is recommended to ensure a therapeutic effect. Long-term treatment in patients who respond has been studied for 6 months and should be considered on an individual patient basis to prevent relapse. The usefulness of long-term treatment should be reassessed regularly. (4) Generalized anxiety disorder: The initial dose is 10mg once daily. The dose may be increased to a maximum of 20mg per day after at least 1 week of treatment, according to the patient's response. A long-term study administering 20mg per day for at least 6 months was conducted in patients who responded to 12 weeks of open-label treatment. The physician should regularly reassess the usefulness of long-term treatment with this drug for each patient. (5) Obsessive-compulsive disorder: The usual dose is 10mg once daily. The dose may be increased to a maximum of 20mg per day according to the patient's response. A long-term study administering 10mg or 20mg per day for at least 24 weeks was conducted in patients who responded to 16 weeks of open-label treatment. Obsessive-compulsive disorder is a chronic condition, and treatment should continue for a sufficient period to ensure recovery from symptoms. If this drug is administered long term, its usefulness and dose should be reassessed regularly for each patient. 2) Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment. Caution is required in patients with severe renal impairment (CLCR < 30㎖/min). 3) Patients with hepatic impairment It is recommended to administer an initial dose of 5mg per day for the first 2 weeks. The dose may be increased to 10mg per day according to the patient's response. 4) Discontinuation When discontinuing this drug, the dose should be gradually reduced over at least 1-2 weeks to avoid the possibility of withdrawal symptoms. 5) Switching from MAO inhibitors used to treat psychiatric disorders When discontinuing an MAO inhibitor used to treat psychiatric disorders and starting treatment with this drug, an interval of at least 14 days should be allowed. Conversely, when starting an MAO inhibitor to treat psychiatric disorders, at least 14 days should elapse after discontinuing this drug. 6) Other MAO inhibitors, such as linezolid or methylene blue Patients receiving linezolid or intravenous methylene blue preparations should not start this drug because of the increased risk of serotonin syndrome. For patients requiring more urgent treatment of a psychiatric condition, including hospitalization, other interventions should be considered. It may be necessary to urgently administer linezolid or intravenous methylene blue preparations to a patient already receiving this drug. If no alternative to linezolid or intravenous methylene blue preparations is available and the benefits of treatment with linezolid or intravenous methylene blue preparations are judged to outweigh the risk of serotonin syndrome in a particular patient, this drug may be discontinued immediately and linezolid or intravenous methylene blue preparations administered. Patients should be monitored for symptoms of serotonin syndrome for 2 weeks after administration of linezolid or intravenous methylene blue preparations, or until 24 hours after the last dose, whichever comes first. Treatment with this drug may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue preparations. The risk associated with administration of methylene blue preparations by non-intravenous routes (oral tablets or local injection), or with intravenous injection of this drug at 1mg/kg or less, is unclear. Nevertheless, clinicians should be aware of the possibility of emergency symptoms of serotonin syndrome with these uses.

This medication is an antidepressant used for the treatment of psychiatric conditions such as major depression.\n\nThere may be an increased risk of suicidal thoughts or behaviors while taking this medication, thus young patients, particularly those aged 18 to 24, should be observed more closely.\n\nThis medication should not be taken with certain drugs, especially MAO inhibitors or pimavanserin, as serious side effects may occur.\n\nPatients with glaucoma or a history of glaucoma should use this medication cautiously as it may increase eye pressure.\n\nInitial use may cause side effects such as insomnia, anxiety, dizziness, nausea, and headaches, which typically subside over time.\n\nThis medication may affect heart rate, so patients with QT interval prolongation or heart disease should consult a physician before use.\n\nDuring treatment, blood sugar control may become difficult, so diabetes patients should regularly monitor their blood sugar levels.\n\nAbruptly discontinuing the medication may lead to withdrawal symptoms such as dizziness, anxiety, and sleep disturbances, so it should be gradually reduced under a physician's guidance.\n\nWomen who are pregnant or breastfeeding should consult a doctor before taking this medication, especially in the later stages of pregnancy, as it may affect the newborn.\n\nThe safety of this medication has not been established in children and adolescents, and it is not recommended for use in these populations.\n\nElderly patients should begin with a lower initial dose and may need to be cautious about driving or operating machinery.\n\nIn cases of overdose, side effects may occur in the central nervous system, heart, and gastrointestinal system, and immediate medical attention should be sought.\n\nThis medication should be stored away from direct sunlight and out of reach of children.

Thrombocytopenia, anaphylactic reaction, inappropriate secretion of antidiuretic hormone, hyperprolactinemia, decreased appetite, increased appetite, weight gain, weight loss, hyponatremia, anorexia, anxiety, restlessness, abnormal dreams, decreased libido, sexual dysfunction, bruxism, agitation, hypersensitivity, panic attack, confusion, aggression, depersonalization, hallucination, mania, suicidal thoughts, suicidal behavior, insomnia, drowsiness, dizziness, paresthesia, tremor, taste disorder, sleep disturbance, syncope, serotonin syndrome, movement disorders, motor impairment, convulsions, psychomotor agitation, akathisia, mydriasis, visual impairment, tinnitus, tachycardia, bradycardia, QT interval prolongation, polymorphic ventricular tachycardia, ventricular arrhythmia, orthostatic hypotension, sinusitis, yawning, epistaxis, nausea, diarrhea, constipation, vomiting, thirst, gastrointestinal bleeding, hepatitis, abnormal liver function tests, increased sweating, urticaria, hair loss, rash, itching, purpura, angioedema, arthralgia, myalgia, rhabdomyolysis, urinary retention, ejaculation disorder, erectile dysfunction, uterine bleeding, menorrhagia, galactorrhea, postpartum hemorrhage, priapism, fatigue, fever, edema, headache, xerostomia, abdominal pain, dyspepsia, enteritis, sensory disturbance, cough, asthma, dyspnea, fracture, palpitations, hypertension, paralysis, extrapyramidal disorders, migraine, chest pain, frequent urination, sedation, tremor, dry mouth, abdominal discomfort, anxiety, visual hallucinations, retroactive anxiety, epileptic seizures, mania, suicidal impulses, suicidal behavior, hostility, aggressiveness, anger, anxiety, restlessness, panic disorder, insomnia, excitement, hostility, impulsiveness, akathisia, hypomania, mania, withdrawal symptoms, dizziness, sleep disturbances, anxiety, nausea, vomiting, tremor, confusion, sweating, headache, diarrhea, palpitations, emotional instability, irritability, visual impairment, QT prolongation, polymorphic ventricular tachycardia, ventricular arrhythmia, persistent sexual dysfunction

This medication is sensitive to light, so it should be stored in a container that prevents light penetration. Additionally, it is important to maintain a temperature between 1 and 30 degrees Celsius when storing the medication, ensuring its effectiveness over time.

Appearance

White oval film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle